Lynkuet (Elinzanetant) for Hot Flashes: How It Works and Who It Helps

Lynkuet is the brand name of elinzanetant, a non-hormonal medicine developed by Bayer for hot flashes and night sweats caused by menopause. Doctors call these vasomotor symptoms (VMS), because they involve the blood vessels and temperature control. Lynkuet was approved in the United States in late 2025 for moderate to severe VMS due to menopause, and it has also been approved in other regions.

It is taken as a capsule once a day at bedtime. Because it contains no estrogen, it is an option for women who cannot or prefer not to use hormone therapy, such as those with certain cancers, blood clot histories or personal preference.

If you are comparing choices, our guide to [Veozah (fezolinetant)](/blog/veozah-fezolinetant-for-hot-flashes-how-it-works) explains the first drug in this new class, and [SSRIs for hot flashes](/blog/ssris-for-hot-flashes-which-ones-work-and-how-well) covers older non-hormonal options.

It works on a brain circuit that becomes overactive when estrogen falls. In the hypothalamus, the brain's thermostat, a group of neurons called KNDy neurons (kisspeptin, neurokinin B and dynorphin) helps regulate temperature. Estrogen normally holds them in check. When estrogen drops, neurokinin B signaling rises and narrows the thermoneutral zone, the comfortable temperature range, so small changes trigger a hot flash.

Elinzanetant is a dual neurokinin-1 and neurokinin-3 (NK1/NK3) receptor antagonist. Blocking NK3 dampens the neurokinin B signal that drives hot flashes. Blocking NK1 may add effects on sleep and mood pathways, which might explain why participants also reported better sleep quality.

This mechanism differs from both hormone therapy and antidepressants. It targets the brain's temperature controller directly, without touching estrogen levels in the body.

The OASIS 1 and 2 trials (Johnson et al., JAMA 2024) were phase 3, randomized, double-blind trials in postmenopausal women with moderate to severe hot flashes. Women took elinzanetant 120 mg or placebo daily for 12 weeks. Elinzanetant reduced hot flash frequency significantly more than placebo at week 4 and week 12; the difference at week 4 was about three fewer hot flashes per day. Women also reported less severe hot flashes and better sleep and quality of life.

The benefit began quickly, with many women noticing improvement in the first week or two, and it lasted through the trial period. OASIS 3 extended treatment for a year and showed continued benefit and no new safety signals, according to published results.

As with all trials, average results hide individual variation. Some women had a large drop in hot flashes, while others had modest improvement. Placebo also helps many women, which is why the difference between drug and placebo is the number that matters.

Yes, sleep improvement was a notable finding. Hot flashes that occur at night, called night sweats, are a major cause of interrupted sleep in menopause. Trial participants taking elinzanetant reported less sleep disturbance on validated questionnaires, and the effect went beyond simply having fewer awakenings from sweats.

That is helpful because poor sleep feeds mood changes, brain fog and weight gain. If night sweats are your main problem, see [what causes night sweats and what helps](/blog/night-sweats-in-menopause-why-they-happen-and-what-helps) for the full menu of options, including cooling strategies and other treatments.

Because the capsule can cause drowsiness, taking it at bedtime turns a side effect into a feature for many women. Still, do not drive or do tasks needing alertness if you feel sleepy the next morning.

The most commonly reported side effects in the OASIS trials were somnolence (sleepiness), fatigue, headache and dizziness. Most were mild to moderate. Serious adverse events were uncommon and similar between elinzanetant and placebo in reported analyses, and long-term data from OASIS 3 did not show new safety concerns.

Related drug Veozah carries an FDA boxed warning for rare liver injury and requires blood tests, which is a reason some women and clinicians look at alternatives. Ask your prescriber what monitoring, if any, applies to Lynkuet under its current U.S. label, since labels can be updated.

Talk to your clinician about interactions. Some medicines that affect the same liver enzymes (CYP3A4) can change elinzanetant levels, and combining it with other sedating drugs or alcohol may increase drowsiness. Tell your prescriber about every prescription and supplement you take.

Good candidates include women with moderate to severe hot flashes who cannot use hormone therapy, do not want it, or have tried it without enough relief. That includes many breast cancer survivors: in OASIS 4 (Simon et al., JAMA 2025), elinzanetant reduced hot flashes in women with, or at high risk of, breast cancer who were taking endocrine therapy such as tamoxifen or aromatase inhibitors, a group that has few effective choices.

It may also suit women whose main complaints are night sweats plus poor sleep. Hormone therapy remains the most effective treatment for hot flashes overall for most healthy women under 60 or within 10 years of menopause; see [the HRT window of opportunity](/blog/the-hrt-window-of-opportunity-why-timing-matters) and [HRT and blood clot risk](/blog/hrt-and-blood-clot-risk-does-delivery-method-matter) to weigh that path.

Lynkuet is not designed to treat vaginal dryness, bone loss or other long-term effects of low estrogen, so some women may still need additional treatments. Coverage and cost can vary, so check with your insurer and prescriber.

Hormone therapy is still the most effective option for most women who can take it. Non-hormonal options are best seen as alternatives rather than replacements. SSRIs and SNRIs such as paroxetine, venlafaxine and escitalopram reduce hot flashes modestly. Gabapentin can help night sweats. Fezolinetant (Veozah) works on NK3 and has good evidence, but requires liver monitoring.

No head-to-head trial has compared elinzanetant directly with fezolinetant, so claims that one is better are not supported yet. Choice comes down to your health history, side effect tolerance, dosing preferences and cost.

Lifestyle changes such as layered clothing, cooling the bedroom, limiting alcohol and spicy food, and regular exercise help some women but are rarely enough for severe symptoms. Supplements like black cohosh have mixed and generally weak evidence.

With so many options, it helps to bring a clear picture of your symptoms and priorities to your appointment. Lea can help you track hot flashes and night sweats, note what makes them worse, and prepare a comparison of hormonal and non-hormonal options tailored to your history.

It can also flag questions to ask about interactions if you take a GLP-1 or other medicines. Lea does not prescribe; it helps you feel prepared and heard.